Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adalimumab induces remissions in Crohn's disease

Adalimumab induces remissions in patients with Crohn's disease who cannot tolerate infliximab, finds the most recent issue of Annals of Internal Medicine.

News image

fiogf49gjkf04

Adalimumab, a fully human tumor necrosis factor antagonist, is an effective treatment Crohn's disease.

It is effective in patients who are naive to the chimeric tumor necrosis factor antagonist, infliximab.

No anti-tumor necrosis factor agent has been evaluated prospectively in patients with Crohn's disease who had responded to another anti-tumor necrosis factor agent and then lost that response or were intolerant of the agent.

Dr William Sandborn and colleagues from Rochester, USA determined whether adalimumab induces remissions more frequently than placebo in Crohn's disease.

The patients had symptoms despite infliximab therapy or who cannot take infliximab because of adverse events.

The team conducted a 4-week, randomized, double-blind, placebo-controlled trial between 2004 and 2005.

21% in the adalimumab group achieved remission at week 4
Annals of Internal Medicine

The team assessed 325 adults 18 to 75 years of age who had a history of Crohn's disease for 4 months or more that was moderate to severe at baseline.

Patients were randomly assigned to receive induction doses of adalimumab, 160 mg and 80 mg, at weeks 0 and 2, respectively, or placebo at the same time points.

The primary end point was induction of remission at week 4.

Decreases in Crohn's Disease Activity Index score by 70 or more and 100 or more points were also measured.

The researchers found a total of 301 patients completed the trial.

The team noted that 21% of patients in the adalimumab group versus 7% of those in the placebo group achieved remission at week 4.

The absolute difference in clinical remission rates was 14% points.

The team found a 70-point response occurred at week 4 in 52% of patients in the adalimumab group versus 34% of patients in the placebo group.

The research team observed that absolute difference in 70-point response rates was 18% points.

The team noted that 2 of 159 patients in the adalimumab group, and 4 of 166 patients in the placebo group discontinued treatment because of adverse events.

The team found that no patients in the adalimumab group, and 4 of 166 patients in the placebo group had a serious infection.

Dr Sandborn's team concluded, "Adalimumab induces remissions more frequently than placebo in adult patients with Crohn's disease who cannot tolerate infliximab or have symptoms despite receiving infliximab therapy."

Ann Int Med 2007: 146(12): 829-38
22 June 2007

Go to top of page Email this page Email this page to a colleague

 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 25 October 2017 
Fecal microbiota transplantation
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us